Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on MedinCell SA (MEDCL – Research Report) on February 26 and set a price ...
Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 25, 2025--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...